乐观
$15.83
情景价格
$13.370
-0.207 (-1.55%)收盘时
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
InMode Ltd is currently priced at $13.97, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 30.293, suggesting the stock is oversold, and the company has experienced a 10.73% decline over the past year. The main risk is the recent downgrade in analyst ratings and the uncertainty surrounding the acquisition bid, which could affect stock performance.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

InMode Anticipates Q3 2026 Financial Results Release

InMode Launches Morpheus8 Cool Technology

Global Medical Aesthetics Market Poised for Significant Growth

Global Medical Aesthetics Market Poised for Significant Growth

InMode Reports Stable Q2 2026 Financial Results Amid Market Challenges
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
InMode Ltd is currently priced at $13.97, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 30.293, suggesting the stock is oversold, and the company has experienced a 10.73% decline over the past year. The main risk is the recent downgrade in analyst ratings and the uncertainty surrounding the acquisition bid, which could affect stock performance.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。